Clinical trial
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes…
NCT00135330 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00135330 |
|---|---|
| Title | An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus |
| Official title | An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | exenatide, rosiglitazone |
| Enrollment | 137 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 26, 2005 |
| Last update posted | Apr 7, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: